title: Psoriatic arthritis: pharmacoeconomic considerations.
abstract: Tumor necrosis factor (TNF) antagonists provide a clinically and economically efficient treatment option for psoriatic arthritis (PsA). PsA is a chronic inflammatory disease affecting the musculoskeletal system that, if untreated, can be disabling due to the progressive joint damage and the considerable impact on functional status and health-related quality of life. Therapies for PsA have been disappointing until recently. Traditional disease-modifying drugs are used to control symptoms, but there is no evidence that they slow the progression of the damage in peripheral joints. The introduction of the TNF-alpha-blocking agents has revolutionized the therapeutic management of PsA. These drugs lessen symptoms and signs of inflammation, enhance quality of life and functional capacity, and hinder the evolution of structural joint damage. TNF-alpha blockers are very expensive and not easily available to all patients, either depending on a national system or private insurance. Nevertheless, recent pharmacoeconomic studies have demonstrated that TNF-alpha blockers are cost-effective treatment options for the musculoskeletal and cutaneous manifestations of psoriatic disease.
authors.affiliation: Rheumatology Department of Lucania, Ospedale San Carlo, Contrada Macchia Romana, Potenza, Italy. ignazioolivieri@tiscalinet.it
authors.forename: Ignazio
authors.initials: I
authors.lastname: Olivieri
authors.forename: Lorenzo Giovanni
authors.initials: LG
authors.lastname: Mantovani
authors.forename: Salvatore
authors.initials: S
authors.lastname: D'Angelo
authors.forename: Angela
authors.initials: A
authors.lastname: Padula
authors.forename: Simona
authors.initials: S
authors.lastname: de Portu
mesh_terms: D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha
references.citation: Br J Dermatol. 2009 Jun;160(6):1264-72
references.pmid: 19120346
references.citation: Rheumatology (Oxford). 2006 Aug;45(8):1029-38
references.pmid: 16782734
references.citation: Curr Rheumatol Rep. 2006 Oct;8(5):355-63
references.pmid: 16973109
references.citation: Arthritis Rheum. 2005 Oct;52(10):3279-89
references.pmid: 16200601
references.citation: Nat Clin Pract Rheumatol. 2007 Dec;3(12):698-706
references.pmid: 18037929
references.citation: Ann Rheum Dis. 2006 Aug;65(8):1038-43
references.pmid: 16439444
references.citation: Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv65-9
references.pmid: 16239392
references.citation: J Rheumatol. 2008 Jan;35(1):137-41
references.pmid: 18050372
references.citation: Arthritis Rheum. 1991 Oct;34(10):1218-27
references.pmid: 1930310
references.citation: Pharmacoeconomics. 2008;26(2):121-9
references.pmid: 18198932
references.citation: J Am Acad Dermatol. 2006 Nov;55(5):829-35
references.pmid: 17052489
references.citation: Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239
references.pmid: 16948890
references.citation: Ann Rheum Dis. 2006 Apr;65(4):423-32
references.pmid: 16126792
references.citation: Best Pract Res Clin Rheumatol. 2002 Dec;16(5):723-39
references.pmid: 12473270
references.citation: Expert Opin Pharmacother. 2009 Feb;10(2):271-82
references.pmid: 19236198
references.citation: Arthritis Rheum. 1997 Oct;40(10):1868-72
references.pmid: 9336423
references.citation: J Rheumatol. 2006 Feb;33(2):210-2
references.pmid: 16465649
references.citation: Br J Rheumatol. 1991 Aug;30(4):245-50
references.pmid: 1863819
references.citation: Rheumatology (Oxford). 2003 Jun;42(6):778-83
references.pmid: 12730539
references.citation: Ann Rheum Dis. 2006 Sep;65(9):1175-83
references.pmid: 16540552
references.citation: Rheumatology (Oxford). 2003 Jul;42(7):909-11
references.pmid: 12826714
references.citation: Arthritis Rheum. 2004 Jul;50(7):2264-72
references.pmid: 15248226
references.citation: Rheumatology (Oxford). 2006 Jul;45(7):790-1
references.pmid: 16705044
references.citation: J Rheumatol. 2008 Apr;35(4):668-73
references.pmid: 18278834
references.citation: Rheumatology (Oxford). 2003 Dec;42(12):1460-8
references.pmid: 14523223
references.citation: J Rheumatol. 2001 Aug;28(8):1842-6
references.pmid: 11508587
references.citation: Rheumatology (Oxford). 2008 Nov;47(11):1664-70
references.pmid: 18725374
references.citation: Lancet. 1997 May 17;349(9063):1436-42
references.pmid: 9164317
references.citation: Rheumatology (Oxford). 2007 Nov;46(11):1729-35
references.pmid: 17956918
references.citation: J Rheumatol. 1990 Jun;17(6):809-12
references.pmid: 2388203
references.citation: Br Med J (Clin Res Ed). 1982 Oct 2;285(6346):949-50
references.pmid: 6811085
references.citation: Rheumatology (Oxford). 2008 May;47(5):718-23
references.pmid: 18400833
references.citation: Arthritis Rheum. 1998 Jun;41(6):1103-10
references.pmid: 9627021
references.citation: J Drugs Dermatol. 2007 Mar;6(3):299-306
references.pmid: 17373192
references.citation: J Rheumatol. 1997 Mar;24(3):511-7
references.pmid: 9058658
references.citation: J Am Acad Dermatol. 1984 Nov;11(5 Pt 2):937-47
references.pmid: 6389615
references.citation: J Rheumatol. 2008 Jul;35(7):1434-7
references.pmid: 18609740
references.citation: Semin Arthritis Rheum. 2002 Feb;31(4):264-70
references.pmid: 11836659
references.citation: J Invest Dermatol. 1979 Nov;73(5 Pt 2):402-13
references.pmid: 501139
references.citation: J Am Acad Dermatol. 2002 Jun;46(6):850-60
references.pmid: 12063481
references.citation: J Rheumatol. 2006 Nov;33(11):2254-9
references.pmid: 16960923
references.citation: J Rheumatol. 2000 May;27(5):1241-6
references.pmid: 10813294